Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy

• Main Authors: Yufei Wang, Anna Jia, Yujing Bi, Yuexin Wang, Qiuli Yang, Yejin Cao, Yan Li, Guangwei Liu
• Format: Article
• Language: English
• Published: MDPI AG 2020-09-01
• Series: Cancers
• Subjects: myeloid-derived suppressor cells; regulatory T cells; immunosuppression; tumor microenvironment; therapy; cancer
• Online Access: https://www.mdpi.com/2072-6694/12/9/2626

Myeloid-derived suppressor cells (MDSCs), which are activated under pathological conditions, are a group of heterogeneous immature myeloid cells. MDSCs have potent capacities to support tumor growth via inhibition of the antitumoral immune response and/or the induction of immunosuppressive cells. In addition, multiple studies have demonstrated that MDSCs provide potential therapeutic targets for the elimination of immunosuppressive functions and the inhibition of tumor growth. The combination of targeting MDSCs and other therapeutic approaches has also demonstrated powerful antitumor effects. In this review, we summarize the characteristics of MDSCs in the tumor microenvironment (TME) and current strategies of cancer treatment by targeting MDSCs.